P17.45 * CARBOPLATIN ALONE AND IN COMBINATION WITH BEVACIZUMAB IN A 5MG/KG EVERY-3-WEEK SCHEDULE, IN PATIENTS WITH RECURRENT GLIOBLASTOMAS: A SINGLE CENTER EXPERIENCE
| Autor: | Gentian Kaloshi, B. Cakani, P. Diamandi, A. Rroji, G. Brace, M. Petrela |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Cancer Research
medicine.medical_specialty Temozolomide Bevacizumab Surrogate endpoint business.industry Single Center medicine.disease Gastroenterology Carboplatin Surgery Poster Presentations chemistry.chemical_compound Oncology chemistry Internal medicine Cohort medicine Neurology (clinical) Progression-free survival business neoplasms Progressive disease medicine.drug |
| Zdroj: | Neuro-Oncology. 16:ii97-ii97 |
| ISSN: | 1523-5866 1522-8517 |
| DOI: | 10.1093/neuonc/nou174.374 |
| Popis: | PURPOSE: Carboplatin (CDDP) and Bevacizumab (BEV) are active in GBM with different profiles of toxicity. In a previous report, we have demonstrated the efficacy of Bevacizumab in a 5mg/kg every 3 week schedule We investigated the efficacy of BEV in combination with CDDP vs CDDP alone in patients with recurrent glioblastomas (GBMs) in a phase II, single-center, non-comparative study. MATERIAL AND METHODS: patients with progression disease (PD) following surgery, RT and TMZ, received CDDP at AUC 5 alone or in combination with BEV 5mg/kg and every 3 weeks for recurrent GBMs between June 2010 and December 2013. Baseline characteristics and outcomes after treatment were recorded. Primary end points were progression-free survival and objective response rate. Secondary end points included safety and overall survival. RESULTS: 48 patients (median age 43 (range 22.4-74.8); M/F 28/20) were enrolled into the study. The median number of cycles in each group was 5 CCDP cycles and 6 CDDP+ BEV (range 2 - 8). No toxicities or intracerebral bleeding were observed. In the BEV + CDDP group 8 patients (35%) had partial response, 9 of them (39%) had minor response, 2 had stable disease and 4 patients (17%) had progressive disease, whereas in the other group 2 patients had partial response, 4 minor responses, 10 had stable disease and 9 experienced PD. Thus, the objective response rate was 64% vs 24%, respectively (p = 0.003). In BEV + CDDP and CDDP alone groups, estimated median PFS was 6.7 vs 5.1 respectively (p = 0.09); and median OS were 7.6 vs 8.3 months (p = 0.66) respectively. CONCLUSIONS: Association of BV to CDDP seemed to improve response rate in recurrent GBMs. However, the clinical benefit of this interesting approach needs a validation in a larger patient cohort. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|